Install
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
- 283,142articles · 365d
- 1+ hour agolatest article
- Sep 13, 2025earliest in window
- 9%with images · 12,384 videos
- 293avg words
- business 172,975
- stocks 118,614
- markets 111,404
- investing 92,534
- stock market 91,208
- business news 75,990
- stock 71,335
- investment 70,396
- stock market news 67,207
- finance 56,900
- technology 54,612
- investment advice 53,959
- companies 49,945
- online trading 49,187
- online investment 43,608
- artificial intelligence 39,102
- online stock trading 37,097
- financial 31,436
- ai 29,685
- inc 20,547
- Economy, Business & Finance 248,816
- Finance & Business 235,636
- News 129,768
- Finance 70,484
- Business & Industrial 29,084
- Health & Wellness 11,551
- Science & Technology 9,382
- Medical 8,069
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
1+ mon, 6+ day ago (771+ words) Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter....
Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg
4+ mon, 2+ week ago (299+ words) Thermo Fisher Scientific has struck a deal to sell its microbiology business to private equity firm Astorg for $1.08 billion. The buyout, which Thermo Fisher disclosed Monday, will see Astorg take over a unit that sells antimicrobial susceptibility testing and culture…...
Ocugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhood
5+ mon, 2+ week ago (281+ words) Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT clinical trial. The trial is for evaluating OCU400, an investigational…...
BRAIN Biotech has Been Granted a Key Patent for Its CRISPR-BMC Genome-editing Technology
5+ mon, 2+ week ago (192+ words) Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up significant potential for further commercial use through licensing BRAIN Biotech offers its technology for strain optimization in customers' production strains Precise genome editing…...
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.
6+ mon, 1+ week ago (859+ words) Apellis laid out a three‑pillar plan focused on a “durable” SYFOVRE franchise in geographic atrophy, an expanding EMPAVELI launch in nephrology, and a planned second‑half clinic entry for a Beam collaboration on an FcRn gene‑editing “once‑and…...
Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation
6+ mon, 3+ week ago (338+ words) Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO…...
Eli Lilly Advances Gene Editing And Lung Cancer Programs With Valuation Upside
6+ mon, 3+ week ago (400+ words) Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported positive topline Phase 3 LIBRETTO-432 results for Retevmo in RET fusion positive early-stage non…...
Eli Lilly Expands Obesity And Gene Programs As Valuation Pulls Back
7+ mon, 1+ week ago (424+ words) Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight loss drugs. The company also announced a research collaboration with Seamless Therapeutics focused on gene editing approaches for hearing loss. A separate…...
Eli Lilly Expands Beyond GLP 1s With Gene Editing And Oncology Bets
7+ mon, 2+ week ago (202+ words) Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene editing therapies for hearing loss. The company also received FDA Breakthrough Therapy designation for an antibody drug conjugate in ovarian cancer. Both developments expand…...
Eli Lilly Uses GLP 1 Strength To Build Broader Drug Pipeline
7+ mon, 1+ week ago (319+ words) Eli Lilly (NYSE:LLY) plans to invest over US$3.5b in a new Pennsylvania manufacturing facility focused on next generation injectable weight loss therapies. The company announced new collaborations with Repertoire Immune Medicines for autoimmune disease programs and Seamless Therapeutics for…...